JMKX003002 will be administered orally

DRUG2 trials

Sponsors

Jemincare

Conditions

HyperphosphatemiaSafety and Tolerability

Phase 1

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

JemincareSafety and Tolerability

Start: 2023-05-09End: 2024-03-31Target: 80Updated: 2023-06-18

Phase 2

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

RecruitingNCT06664125

JemincareHyperphosphatemia

Start: 2024-12-30End: 2025-09-30Target: 50Updated: 2025-02-03